Trending Now
The FDA Agrees With Aldeyra Therapeutics Inc. (NASDAQ:ALDX) On RASP Inhibitor...
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) has announced that it has reached an agreement with the FDA regarding the uses of reactive aldehyde species (RASP) as...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Receive Approval From European Commission For Expanded...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has announced that it has received approval from the EU for KALYDECO® granules label extension. The extension includes treatment of...
MAKE IT MODERN
LATEST REVIEWS
Global Blood Therapeutics Inc (NASDAQ:GBT) Garners The Rare Impact Award For...
Global Blood Therapeutics Inc (NASDAQ:GBT) is on the right track as far as the development of its Oxbryta® (voxelotor) tablets is concerned. The tablets...
MAKE IT MODERN
PERFORMANCE TRAINING
Ocugen Inc. (NASDAQ:OCGN) Announce Discontinuation Of Third Phase OCU300 Trial In Treatment of oGVHD
Ocugen Inc. (NASDAQ:OCGN) has announced that it has decided to stop the third phase OCU300 trials for ocular Graft versus Host Disease (oGVHD).
Ocugen discontinues...
Ionis Pharmaceuticals (NASDAQ:IONS) Commences Clinical Trial For Proprietary Antisense Treatment For ALS
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) has announced the dosing of the first patient with its investigational antisense ION541, also called BIIB105. The company is developing...
Amarin Corporation plc (NASDAQ:AMRN) is Playing the Next Game
The story right now for Amarin
Corporation plc (NASDAQ:AMRN) continues to be one of our favorites. It
represents the best of the dream that...
PTC Therapeutics, Inc. (NASDAQ: PTCT) Announce That Brazil’s Drug Market Regulation Chamber Has Granted...
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that Waylivra has obtained Category 1 classification from the Câmara de Regulaço do Mercado de Medicamentos -...
Cassava Sciences Inc (NASDAQ:SAVA) Expects To Release Clinical Results Of Phase 2b Trial To...
Cassava Sciences Inc (NASDAQ:SAVA) reported a net loss of $1.1 million in Q2 2020. The company expects to use $5 million in 2020 for...
MAKE IT MODERN
